AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12164031 — intervention group
Group type: COMPARATOR
Intervention: Daily oral iron supplementation (100 mg elemental iron)
Number of subjects: 92
Study 9165507 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (Fareston)
Number of subjects: 830
Study 9165507 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (Nolvadex)
Number of subjects: 830
Study 8199073 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent counselling by an experienced psychotherapist
Number of subjects: 57
Study 8199073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no independent counselling)
Number of subjects: 57
Study 8199073 — intervention group
Group type: EXPERIMENTAL
Intervention: Termination of pregnancy
Number of subjects: 57
Study 3555430 — intervention group
Group type: COMPARATOR
Intervention: Symmetric medial rectus recessions with posterior fixation sutures
Number of subjects: 0
Study 3555430 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric medial rectus recessions without posterior fixation sutures, augmented according to formula
Number of subjects: 0
Study 29738462 — intervention group
Group type: COMPARATOR
Intervention: acidified milk protein drink
Number of subjects: 29
Study 29738462 — intervention group
Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 29
Study 27354202 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (tricyclic antidepressant)
Number of subjects: 39
Study 27354202 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill with conditioned stimulus (novel-tasting drink)
Number of subjects: 39
Study 24742146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) training, 5 days per week for 1 hour per day for 12 weeks
Number of subjects: 206
Study 24742146 — intervention group
Group type: COMPARATOR
Intervention: No specific exercise (Control group)
Number of subjects: 206
Study 24370801 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 71
Study 24370801 — intervention group
Group type: COMPARATOR
Intervention: Low-dose fentanyl
Number of subjects: 71
Study 20216117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) dosing regimens (fixed and concentration-controlled)
Number of subjects: 219
Study 20216117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 219
Study 18480832 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day automatic ambulatory BP monitoring (ABPM) in prediabetics
Number of subjects: 0
Study 18480832 — intervention group
Group type: COMPARATOR
Intervention: 7-day automatic ambulatory BP monitoring (ABPM) in normoglycemics
Number of subjects: 0
Study 15876471 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic screening strategy (saliva sample taken at home)
Number of subjects: 3000
Study 15876471 — intervention group
Group type: COMPARATOR
Intervention: Phenotypic screening strategy (transferrin saturation on blood sample taken at GP surgery)
Number of subjects: 3000
Study 14696994 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice amplification using the ChatterVox portable amplifier (VA; n = 25)
Number of subjects: 64
Study 14696994 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonance therapy (RT; n = 19)
Number of subjects: 64
Study 14696994 — intervention group
Group type: COMPARATOR
Intervention: Respiratory muscle training (RMT; n = 20)
Number of subjects: 64
Study 10559510 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 90
Study 10559510 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (controls)
Number of subjects: 90
Study 8723140 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) type A, 50 U
Number of subjects: 25
Study 8723140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1912429 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol 200 micrograms q.i.d. for 4-8 weeks
Number of subjects: 50
Study 1912429 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 7037301 — intervention group
Group type: EXPERIMENTAL
Intervention: IMV4
Number of subjects: 9
Study 7037301 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP10
Number of subjects: 9
Study 7037301 — intervention group
Group type: COMPARATOR
Intervention: IPPV12
Number of subjects: 9
Study 7037301 — intervention group
Group type: COMPARATOR
Intervention: PEEP0
Number of subjects: 9
Study 30246555 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction limb
Number of subjects: 20
Study 30246555 — intervention group
Group type: COMPARATOR
Intervention: Control limb
Number of subjects: 20
Study 29801398 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 100
Study 29801398 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 100
Study 26231884 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (4-7 days/week)
Number of subjects: 87
Study 26231884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 87
Study 26231884 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 87
Study 25099167 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR (Canadian C-Spine Rule)
Number of subjects: 378
Study 25099167 — intervention group
Group type: COMPARATOR
Intervention: CCHR (Canadian CT Head Rule)
Number of subjects: 378
Study 22291042 — intervention group
Group type: EXPERIMENTAL
Intervention: VRT and tDCS
Number of subjects: 8
Study 22291042 — intervention group
Group type: COMPARATOR
Intervention: VRT and sham
Number of subjects: 8
Study 19465188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sugar/low-fiber meal
Number of subjects: 10
Study 19465188 — intervention group
Group type: COMPARATOR
Intervention: Low-sugar/high-fiber meal
Number of subjects: 10
Study 17848323 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic‐assisted vaginal hysterectomy (LAVH)
Number of subjects: 81
Study 17848323 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy hysterectomy
Number of subjects: 81
Study 15220165 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural oxycodone 6 mg day(‐1)
Number of subjects: 75
Study 15220165 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural oxycodone 12 mg day(‐1)
Number of subjects: 75
Study 15220165 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 6 mg day(‐1)
Number of subjects: 75
Study 11399136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup feeding of breast milk
Number of subjects: 14
Study 11399136 — intervention group
Group type: COMPARATOR
Intervention: Bottle feeding of breast milk
Number of subjects: 14
Study 9921699 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine and subsequent lithium addition
Number of subjects: 100
Study 9921699 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine and subsequent lithium addition
Number of subjects: 100
Study 9921699 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 100
Study 9921699 — intervention group
Group type: COMPARATOR
Intervention: Lithium addition to either imipramine or mirtazapine
Number of subjects: 100
Study 7906759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subcitrate, tetracycline, and metronidazole (1-week course)
Number of subjects: 132
Study 7906759 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (4 weeks) with bismuth subcitrate, tetracycline, and metronidazole (1-week course)
Number of subjects: 132
Study 3290622 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 16
Study 3290622 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (UCT)
Number of subjects: 16
Study 3290622 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 16
Study 3290622 — intervention group
Group type: COMPARATOR
Intervention: UCT
Number of subjects: 16
Study 1375801 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (12 mg daily)
Number of subjects: 44
Study 1375801 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (10 mg daily)
Number of subjects: 44
Study 196232 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cerebellar stimulation
Number of subjects: 8
Study 196232 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cerebral cortical stimulation
Number of subjects: 8
Study 196232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar stimulation
Number of subjects: 8
Study 196232 — intervention group
Group type: COMPARATOR
Intervention: Cerebral surface stimulation
Number of subjects: 8
Study 31707288 — intervention group
Group type: EXPERIMENTAL
Intervention: BresoDx
Number of subjects: 233
Study 31707288 — intervention group
Group type: COMPARATOR
Intervention: PSG
Number of subjects: 233
Study 31590437 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fiber, Low-GI (HF-LGI) meal
Number of subjects: 11
Study 31590437 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI meals (including HF-LGI and LF-LGI)
Number of subjects: 11
Study 31590437 — intervention group
Group type: COMPARATOR
Intervention: Low-Fiber, High-GI (LF-HGI) meal
Number of subjects: 11
Study 31590437 — intervention group
Group type: COMPARATOR
Intervention: High-Fiber, High-GI (HF-HGI) meal
Number of subjects: 11
Study 31590437 — intervention group
Group type: COMPARATOR
Intervention: Low-Fiber, Low-GI (LF-LGI) meal
Number of subjects: 11
Study 28749198 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy skills training with simulated patients (SPs)
Number of subjects: 158
Study 28749198 — intervention group
Group type: COMPARATOR
Intervention: History course (Control)
Number of subjects: 158
Study 26059012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 2985
Study 26059012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2985
Study 23852309 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 820
Study 23852309 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 820
Study 21476127 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaolin-based haemostatic bandage
Number of subjects: 200
Study 21476127 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 200
Study 19439062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-based hydration
Number of subjects: 2633
Study 19439062 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 2633
Study 18693590 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole pharmacologic stress during myocardial perfusion imaging
Number of subjects: 30
Study 18693590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild perfusion defects
Number of subjects: 30
Study 18693590 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate perfusion defects
Number of subjects: 30
Study 18693590 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe perfusion defects
Number of subjects: 30
Study 18693590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed defects
Number of subjects: 30
Study 18693590 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversible defects (mild to moderate)
Number of subjects: 30
Study 15008644 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory fit induced by strategic framing of message arguments
Number of subjects: 0
Study 15008644 — intervention group
Group type: EXPERIMENTAL
Intervention: Source unrelated to the message
Number of subjects: 0
Study 15008644 — intervention group
Group type: COMPARATOR
Intervention: Control group with salient source of feeling right before message exposure
Number of subjects: 0
Study 15008644 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative message-related thoughts
Number of subjects: 0
Study 11469475 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity home‐based progressive strength training program
Number of subjects: 46
Study 11469475 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education program (attention control)
Number of subjects: 46
Study 9628709 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (lifting instructions) and lumbar support
Number of subjects: 282
Study 9628709 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 282
Study 9628709 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar support
Number of subjects: 282
Study 9628709 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 282
Study 9628709 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar support (in subgroup with low back pain at baseline)
Number of subjects: 282
Study 7511740 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril, lisinopril, or perindopril (ACE inhibitors) for 8-12 weeks
Number of subjects: 52
Study 7511740 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 52
Study 7511740 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor monotherapy
Number of subjects: 52
Study 7511740 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 52
Study 3257688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole and trimethoprim (Bactrim)
Number of subjects: 1
Study 3257688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 29287673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bain's system at 5L.min‐1
Number of subjects: 0
Study 29287673 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson A at 5L.min‐1
Number of subjects: 0
Study 29287673 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle system at 5L.min‐1
Number of subjects: 0
Study 29287673 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson A at 10L.min‐1
Number of subjects: 0
Study 29287673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bain's system at 10L.min‐1
Number of subjects: 0
Study 29287673 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle system at 10L.min‐1
Number of subjects: 0
Study 28593720 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogen-rich natural preparation Karinat
Number of subjects: 0
Study 28593720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26248676 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vaccination with rVSV‐ZEBOV (one dose of 2×10^7 plaque‐forming units, administered intramuscularly)
Number of subjects: 7651
Study 26248676 — intervention group
Group type: COMPARATOR
Intervention: Delayed vaccination with rVSV‐ZEBOV
Number of subjects: 7651
Study 26248676 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vaccination with rVSV‐ZEBOV
Number of subjects: 7651
Study 23065050 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-G Whitacre spinal needle
Number of subjects: 60
Study 23065050 — intervention group
Group type: COMPARATOR
Intervention: Quincke spinal needle
Number of subjects: 60
Study 23065050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Whitacre and Quincke needles with 1.2 ml of 0.5% plain bupivacaine
Number of subjects: 60
Study 22256634 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120
Study 22256634 — intervention group
Group type: COMPARATOR
Intervention: Western medication (Glucosamine Hydrochloride capsules, 2 capsules, 3 times per day)
Number of subjects: 120
Study 19301989 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR (50 or 100 mg, q4-6h, p.o.)
Number of subjects: 878
Study 19301989 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone IR (10 or 15 mg, q4-6h, p.o.)
Number of subjects: 878
Study 19301989 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR
Number of subjects: 878
Study 19301989 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone IR
Number of subjects: 878
Study 16702891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pagoclone (4.8 mg)
Number of subjects: 23
Study 16702891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pagoclone (1.2 mg)
Number of subjects: 23
Study 16702891 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (30 mg)
Number of subjects: 23
Study 16702891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 15349004 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75 to 225 mg/d)
Number of subjects: 272
Study 15349004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 11392066 — intervention group
Group type: COMPARATOR
Intervention: 20 mg chlorpheniramine (CPM) before surgery (Control group C, n = 22)
Number of subjects: 64
Study 11392066 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg dextromethorphan (DM) and 20 mg CPM before surgery (group B, n = 22)
Number of subjects: 64
Study 9034938 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg b.i.d. (N2)
Number of subjects: 6
Study 9034938 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg b.i.d. (R2)
Number of subjects: 6
Study 9034938 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg q.h.s. (N1)
Number of subjects: 6
Study 9034938 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg q.h.s. (R1)
Number of subjects: 6
Study 9034938 — intervention group
Group type: COMPARATOR
Intervention: placebo (P)
Number of subjects: 6
Study 1325613 — intervention group
Group type: COMPARATOR
Intervention: rHuEpo at an initial dose of 50 U/kg thrice weekly, adjusted to maintain Hb 105-120 g/l (group 1)
Number of subjects: 98
Study 1325613 — intervention group
Group type: COMPARATOR
Intervention: Usual dose of rHuEpo adjusted to maintain Hb 105-120 g/l (group 2)
Number of subjects: 98
Study 1325613 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo therapy (both groups)
Number of subjects: 98
Study 1325613 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo therapy (group 1)
Number of subjects: 98
Study 6381612 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam plus ticarcillin (M/T)
Number of subjects: 108
Study 6381612 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin plus ticarcillin (T/T)
Number of subjects: 108
Study 30075543 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopic sputum suction
Number of subjects: 0
Study 30075543 — intervention group
Group type: COMPARATOR
Intervention: General sputum suction
Number of subjects: 0
Study 24970718 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 26
Study 24970718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 26088854 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive volume of intraoperative fluid (≤8 mL/kg/h)
Number of subjects: 16
Study 26088854 — intervention group
Group type: COMPARATOR
Intervention: Liberal volume of intraoperative fluid (>8 mL/kg/h)
Number of subjects: 16
Study 23819476 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus additional early initiation of secondary prevention drugs (blood-pressure lowering protocol, simvastatin 40 mg, dipyridamole 200 mg m/r bd)
Number of subjects: 100
Study 23819476 — intervention group
Group type: COMPARATOR
Intervention: Usual care (initiation of aspirin and referral to a TIA clinic)
Number of subjects: 100
Study 23819476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial
Number of subjects: 100
Study 23819476 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy sub-study
Number of subjects: 100
Study 20886725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 0
Study 18637030 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction regimen including fludarabine, arabinosyl cytosine and idarubicin, with or without etoposide (FLAI/FLAIE)
Number of subjects: 224
Study 16173864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with homework assignments
Number of subjects: 60
Study 12695287 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg BID)
Number of subjects: 39
Study 12695287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9893077 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy
Number of subjects: 330
Study 7751429 — intervention group
Group type: EXPERIMENTAL
Intervention: Indenolol (120 mg)
Number of subjects: 12
Study 7751429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2208416 — intervention group
Group type: EXPERIMENTAL
Intervention: Xintongkang capsule
Number of subjects: 267
Study 2208416 — intervention group
Group type: COMPARATOR
Intervention: Persantin and aspirin (Control)
Number of subjects: 267
Study 6255844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 12
Study 6255844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6255844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (after placebo)
Number of subjects: 12
Study 31355456 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept alone
Number of subjects: 0
Study 31355456 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept complexed with APRIL
Number of subjects: 0
Study 31355456 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimeric form of atacicept
Number of subjects: 0
Study 31355456 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 27710700 — intervention group
Group type: EXPERIMENTAL
Intervention: Back extensor strengthening exercises
Number of subjects: 183
Study 27710700 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy and weight-bearing and balance-training exercises (Control)
Number of subjects: 183
Study 25943440 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity aerobic exercise (UEAE)
Number of subjects: 52
Study 25943440 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 52
Study 23766391 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal mind-body program (MMMT)
Number of subjects: 64
Study 23766391 — intervention group
Group type: COMPARATOR
Intervention: Walking intervention
Number of subjects: 64
Study 21256048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg
Number of subjects: 405
Study 21256048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg add-on to bosentan
Number of subjects: 405
Study 21256048 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 405